Filing Flows › 4D Molecular Therapeutics (FDMT) › Stock forecast & fair value
4D Molecular Therapeutics (FDMT) stock forecast and price target
4D Molecular Therapeutics (FDMT) trades at $12.25. 11 analysts' median price target is $28.00 (+129%), from $18.00 to $37.00.
4D Molecular Therapeutics' latest quarter
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for FDMT stock?
The median of 11 analysts' 12-month targets is $28.00, +129% from $12.25; the range is $18.00 to $37.00. The average rating is none.
Does 4D Molecular Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 25% of the quarters on record.
Is FDMT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.